Abstract
Pharmacophore searches have become a popular tool for virtual screening of libraries to identify novel active substances that can be potentially developed into drugs. While they have been applied for years on common drug targets, their application in the discovery of protein-protein interaction inhibitors remains limited.
This review describes current pharmacophore modelling methods applied in the discovery of novel inhibitors targeting protein-protein interactions. We first address the mimicry of protein-protein interactions with their respective inhibitors as observed in crystal structure complexes. This mimicry can be exploited to derive a pharmacophore query from protein-protein complex structures. We then discuss several cases where pharmacophore queries were utilized for the discovery of first-in-class inhibitors of their respective protein-protein interaction targets. These examples have demonstrated the usefulness of pharmacophore modelling in the quest for protein-protein interaction inhibitors.
Keywords: Drug discovery, protein-protein interaction, small molecule inhibitor, pharmacophore modeling, virtual screening, LEDGINS, HIV, integrase, LEDGF/p75, Bcr-Abl, 14-3-3, lysozyme, PliC, PUMA, reverse transcriptase, SMPPII.
Current Pharmaceutical Design
Title:Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Volume: 18 Issue: 30
Author(s): Arnout Voet and Kam Y.J. Zhang
Affiliation:
Keywords: Drug discovery, protein-protein interaction, small molecule inhibitor, pharmacophore modeling, virtual screening, LEDGINS, HIV, integrase, LEDGF/p75, Bcr-Abl, 14-3-3, lysozyme, PliC, PUMA, reverse transcriptase, SMPPII.
Abstract: Pharmacophore searches have become a popular tool for virtual screening of libraries to identify novel active substances that can be potentially developed into drugs. While they have been applied for years on common drug targets, their application in the discovery of protein-protein interaction inhibitors remains limited.
This review describes current pharmacophore modelling methods applied in the discovery of novel inhibitors targeting protein-protein interactions. We first address the mimicry of protein-protein interactions with their respective inhibitors as observed in crystal structure complexes. This mimicry can be exploited to derive a pharmacophore query from protein-protein complex structures. We then discuss several cases where pharmacophore queries were utilized for the discovery of first-in-class inhibitors of their respective protein-protein interaction targets. These examples have demonstrated the usefulness of pharmacophore modelling in the quest for protein-protein interaction inhibitors.
Export Options
About this article
Cite this article as:
Voet Arnout and Y.J. Zhang Kam, Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651616
DOI https://dx.doi.org/10.2174/138161212802651616 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Matrix Metalloproteinases
Current Medicinal Chemistry Future of Spermatogonial Stem Cell Culture: Application of Nanofiber Scaffolds
Current Stem Cell Research & Therapy De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Lead Generation for Human Mitotic Kinesin Eg5 Using Structure-based Virtual Screening and Validation by In-vitro and Cell-based Assays
Current Computer-Aided Drug Design Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Pulmonary Arterial Hypertension
Current Vascular Pharmacology Editorial Review of 2012
Current Radiopharmaceuticals RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Direct Effect of Testosterone on NGEP and LM O1 Expression in LNCaP Prostate Cancer Cells
Current Biomarkers (Discontinued) Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Pharmacokinetic Properties of Rituximab
Reviews on Recent Clinical Trials